Puma Biotechnology Sees Q3 Revenue $50M-$53M Vs $57.85M Est.; FY24 Revenue $183M-$190M Vs $217.63M Est.
Portfolio Pulse from Benzinga Newsdesk
Puma Biotechnology has revised its Q3 and FY24 revenue estimates downward. Q3 revenue is now expected to be $50M-$53M, below the $57.85M estimate. FY24 revenue is projected at $183M-$190M, compared to the $217.63M estimate.
August 01, 2024 | 9:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Puma Biotechnology has revised its Q3 and FY24 revenue estimates downward. Q3 revenue is now expected to be $50M-$53M, below the $57.85M estimate. FY24 revenue is projected at $183M-$190M, compared to the $217.63M estimate.
The downward revision of revenue estimates for both Q3 and FY24 is likely to negatively impact investor sentiment and the stock price in the short term. The new estimates are significantly lower than previous expectations, indicating potential challenges in the company's performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100